Long-Term Survival Benefit after Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia

Nico Gagelmann,Rashit Bogdanov,Friedrich Stölzel,Christina Rautenberg, Victoria Panagiota,Heiko Becker,Aleksandar Radujkovic,Thomas Luft,Maximilian Christopeit,Jürgen Finke,Uwe Platzbecker,Markus Ditschkowski,Thomas Schroeder,Michael Koldehoff, Michael Heuser,Guido Kobbe,Dietrich W. Beelen,Ulrich Germing,Nicolaus Kröger

Transplantation and Cellular Therapy（2021）

引用 0|浏览1

暂无评分

摘要

•Allogeneic hematopoietic cell transplantation (allo-HCT) may provide a long-term survival benefit compared with nontransplantation strategies in higher-risk chronic myelomonocytic leukemia (CMML) according to CMML-specific prognostic scoring system (CPSS).•The CPSS provides only modest utility for risk stratification in the transplantation setting.•Better HCT-specific risk assessment is needed to identify patients who may benefit the most to eventually facilitate patient counseling.

查看译文

关键词

Chronic myelonocytic leukemia,Allogeneic hematopoietic stem cell transplantation,Supportive care,Hypomethylating agents,Prognosis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要